Cyntegrity Launches MyRBQM

Results across two studies showed patients sustained stable, long-term remission.

Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.

The INTerpath-009 clinical trial will evaluate the combination as adjuvant treatment for patients with NSCLC who previously received neoadjuvant Keytruda plus platinum-based chemotherapy.

Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.

Omvoh (mirikizumab) becomes the first IL23p19 antagonist to show multi-year, long-term sustained efficacy in both ulcerative colitis and Crohn disease, with Phase III trials showing high rates of clinical and endoscopic remission with a consistent safety profile.

Ebglyss (lebrikizumab-lbkz) shows significant efficacy in reducing skin symptoms and itch in moderate-to-severe atopic dermatitis patients, including those who previously discontinued Dupixent.